ClinicalTrials.gg
CompletedNCT06408454Updated May 10, 2024

Interleukin- 17 (IL-17), Bcl-3, and NF-kappa-B Inhibitor Zeta (IκBζ) Expression Levels in the Psoriasis Patients

An observational study in Psoriasis and Periodontal Diseases, sponsored by Kahramanmaras Sutcu Imam University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Kahramanmaras Sutcu Imam University · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
12
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aimed to compare the levels of IL-17 (interleukin- 17), Bcl-3 (B-cell lymphoma 3-encoded protein), and IκBζ (NF-kappa-B inhibitor zeta) in the gingival crevicular fluid of psoriatic and healthy individuals and the clinical parameters such as periodontal health, gingival index, plaque index and mobility (using periotest device)in the patient and control groups.

Read the detailed description

Patient selection

Ten patients previously diagnosed with psoriasis who visited the Van 100. Yıl University Faculty of Dentistry Oral and Maxillofacial Radiology dental clinic were included in the study. Non-psoriasis individuals were selected from volunteer patients attending the same dental clinic.

Clinical measurements

A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.

Gingival crevicular fluid (GCF) collection

Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.

02

Conditions studied

  • Psoriasis
  • Periodontal Diseases

Keywords

  • psoriasis
  • gene expression
  • periodontal health
03

In context

Psoriasis

1,928 studies on the registry are indexed under Psoriasis; 234 are open to participants now.

This study's enrollment of 12 is below the median of 200 across 400 observational studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Kahramanmaras Sutcu Imam University is the lead sponsor of 195 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The patients living in Eastern region of Turkey and visiting our clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients previously diagnosed with psoriasis
  • Adults who are 18 years of age or older
  • Patients having at least 11 teeth

Exclusion criteria

Exclusion Criteria:

  • Patients with any known systemic disease other than psoriasis
  • Patients who had received antibiotic, nonsteroidal anti-inflammatory, and/or immunomodulatory therapy within the last three months
  • Patients who had received radiotherapy and/or chemotherapy within the last years
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
12 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Psoriasis patients

    IL-17, Bcl-3, IκBζ gene expression levels were examined

    Diagnostic Test: Gingival crevicular fluid collection · Diagnostic Test: periodontal test

  • Control group

    IL-17, Bcl-3, IκBζ gene expression levels were examined

    Diagnostic Test: Gingival crevicular fluid collection · Diagnostic Test: periodontal test

Interventions

  • Diagnostic testGingival crevicular fluid collection

    Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.

  • Diagnostic testperiodontal test

    A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.

06

What researchers measure

Primary outcomes

  1. Level of Gene expression

    In the real-time polymerase chain reaction (PCR) results of the β-actin gene, which was used as a housekeeping gene in the study, the automatic threshold value was determined by the device as 0.02. It was observed that all samples were above the threshold value and gave a ct value. According to the housekeeping gene, IL-17, IκBζ, and Bcl-3gene expression values were determined.

    Time frame: Sample collection during examination, approximately 2 months

Secondary outcomes

  1. Plaque index

    To determine the plaque index of the patients, their dental plaque thickness was evaluated by probing surfaces of selected teeth using a periodontal probe. Scores range from 0 to 3.

    Time frame: Baseline, week 2

  2. Gingival index

    To determine the gingival index of the patients, gingival bleeding caused by running a Williams periodontal probe inside the pocket on the mesial, distal, buccal, and palatal surfaces of selected teeth was evaluated. Scores range from 0 to 3.

    Time frame: Baseline, week 2

  3. Clinical attachment level

    This parameter represents the extent of periodontal support that has been lost around a tooth and is measured with the periodontal probe as the distance from the cemento-enamel junction (CEJ) to the base of the pocket (in mm)

    Time frame: Baseline, week 2

  4. Tooth Mobility

    The amount of tooth mobility can be displayed by a value called periotest value (PTV) ranging from -8 to +50

    Time frame: Baseline, week 2

07

Study locations

1 site
  • Ayşe Gül Öner Talmaç
    Kahramanmaraş, Onikişubat 46000, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06408454
Responsible party
AYŞE GÜL ÖNER TALMAÇ (assistant professor, Kahramanmaras Sutcu Imam University) — Principal investigator
First posted
May 10, 2024
Start date
Feb 1, 2023
Primary completion
Apr 10, 2023
Completion
Aug 15, 2023
Last update
May 10, 2024

Study contacts

Ayşe Gül Öner Talmaç, PhD
principal investigator · Faculty of Dentistry, Kahraman Maraş Sütçü İmam University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion